91% of medical technology and 85% of biopharma executives expect new technologies to have a positive impact on the industry
NEW YORK–(BUSINESS WIRE)–Accenture’s (NYSE: ACN) Life Sciences Technology Vision 2022 report explores the technology trends that will transform how biopharmaceutical and medical technology companies solve manufacturing and device problems, improve equity in clinical trial participation and build more resilient supply chains to provide patients and healthcare professionals with more personalized experiences.
The metaverse is an evolving and expanding continuum on multiple dimensions — digital and physical — that comprises technologies including extended reality, blockchain, artificial intelligence, digital twins, non-fungible tokens, and smart devices. According to the report, life sciences leaders (91% of medical technology executives and 85% biopharma executives) expect the metaverse to have a positive impact on their organizations and nearly half of the biopharma executives surveyed believe the metaverse will have a breakthrough or transformational impact on their organizations.
Petra Jantzer, global industry life sciences lead at Accenture, said, “We are in the early days of the metaverse, and the technology innovations we implement today — the solutions, products and services companies offer, how they develop and distribute them and how they fundamentally operate their organizations — are the building blocks of the future for life sciences. Industry leaders are pioneering a new digital future for how people and enterprises interact, and many of the rules remain undefined. It is critical that life sciences companies take steps to proactively and responsibly shape the metaverse continuum.”
To help life sciences companies design, execute and accelerate their metaverse journeys, Accenture recently launched the Accenture Metaverse Continuum business group, which combines metaverse-skilled professionals and market-leading capabilities in customer experience, digital commerce, extended reality, blockchain, digital twins, artificial intelligence, and computer vision.
In the report, four technology trends that underpin the metaverse continuum are explored.
WebMe illustrates how the internet is being reimagined with the metaverse as a platform for digital experiences that provide boundless places where people can meet and interact, and Web3 is reinventing how data can be owned by individuals and moved with the person and not the platform. In the future, a new generation of digital devices will integrate into the metaverse and could include smart technology in everyday objects like home appliances, and ‘smart’ cars that provide salient data on healthy human behaviors along with medically regulated devices such as Donisi, which can simultaneously detect and analyze multiple bio-parameters.
The Programmable World tracks how technology is being threaded through our physical environments in three layers: connected, experiential, and material. Nearly nine-in-10 of the MedTech and biopharma executives surveyed believe that programming the physical environment will emerge as a competitive differentiation in their industry. Augmented reality, 5G, ambient computing, 3D printing, and smart materials are converging in sophisticated ways, turning the physical world into an environment that is as smart, customizable, and as programmable as the digital one.
The Unreal explores the “unreal” qualities that are becoming fundamental to artificial intelligence (AI), and even data, making the synthetic seem authentic. Synthetic data is being used to train AI models in ways that real-world data practically cannot or should not. Synthetic data can represent patient datasets for use in research, training, or other applications. This realistic (yet unreal) data can be shared, maintaining the same statistical properties while protecting confidentiality and privacy. It can be developed to accommodate increased diversity to counter bias, thus overcoming the pitfalls of real-world data. More than nine-tenths of biopharma (92%) and MedTech (91%) executives report that their organization is dependent on AI technologies to function effectively.
- Computing the Impossible is the emergence of a new class of machines –quantum computing– stretching the boundaries of what computers can do. Problems once thought impossible to solve because they require computing large, complex datasets are now in the realm of the possible. Nearly all the surveyed biopharma (94%) and MedTech (96%) executives agree that their organization is pivoting in response to the unprecedented computational power that is becoming available.
The Life Sciences Technology Vision 2022 report can be accessed here.
About the Methodology
For the 2022 report, the research process included gathering input from the Technology Vision External Advisory Board, a group comprising more than two dozen experienced individuals from the public and private sectors, academia, venture capital firms, and entrepreneurial companies. In addition, the Technology Vision team conducted interviews with technology luminaries and industry experts, as well as many Accenture business leaders. In parallel, Accenture Research conducted a global survey of 24,000 consumers and 4,650 C-level executives and directors across 35 countries and 23 industries. The biopharmaceutical industry sample comprised 100 executives in eight countries (China, France, Germany, India, Japan, Switzerland, the United Kingdom and the United States). Surveys were fielded in April 2022. The medical technology industry sample comprised 100 executives in eight countries (China, France, Germany, India, Japan, Switzerland, the United Kingdom and the United States). Surveys were fielded in April 2022.
Accenture is a global professional services company with leading capabilities in digital, cloud, and security. Combining unmatched experience and specialized skills across more than 40 industries, we offer Strategy and Consulting, Technology and Operations services, and Accenture Song — all powered by the world’s largest network of Advanced Technology and Intelligent Operations centers. Our 710,000 people deliver on the promise of technology and human ingenuity every day, serving clients in more than 120 countries. We embrace the power of change to create value and shared success for our clients, people, shareholders, partners, and communities. Visit us at accenture.com.
Copyright © 2022 Accenture. All rights reserved. Accenture and its logo are trademarks of Accenture. This content is provided for general information purposes and is not intended to be used in place of consultation with our professional advisors. This document refers to marks owned by third parties. All such third-party marks are the property of their respective owners. No sponsorship, endorsement or approval of this content by the owners of such marks is intended, expressed or implied.